Amicus Therapeutics Current Ratio 2007-2021 | FOLD

Amicus Therapeutics current ratio from 2007 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Amicus Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.48B $0.11B 4.29
2021-03-31 $0.50B $0.10B 5.05
2020-12-31 $0.58B $0.13B 4.47
2020-09-30 $0.59B $0.11B 5.24
2020-06-30 $0.38B $0.11B 3.55
2020-03-31 $0.41B $0.09B 4.45
2019-12-31 $0.52B $0.13B 4.04
2019-09-30 $0.58B $0.09B 6.20
2019-06-30 $0.64B $0.09B 7.09
2019-03-31 $0.48B $0.07B 7.33
2018-12-31 $0.55B $0.09B 6.40
2018-09-30 $0.60B $0.07B 9.12
2018-06-30 $0.58B $0.05B 10.88
2018-03-31 $0.59B $0.14B 4.21
2017-12-31 $0.39B $0.07B 5.60
2017-09-30 $0.43B $0.07B 6.32
2017-06-30 $0.24B $0.10B 2.39
2017-03-31 $0.30B $0.11B 2.70
2016-12-31 $0.34B $0.11B 3.07
2016-09-30 $0.22B $0.09B 2.59
2016-06-30 $0.22B $0.08B 2.71
2016-03-31 $0.17B $0.06B 2.62
2015-12-31 $0.22B $0.07B 2.94
2015-09-30 $0.24B $0.04B 6.69
2015-06-30 $0.37B $0.02B 21.60
2015-03-31 $0.15B $0.02B 7.20
2014-12-31 $0.16B $0.02B 7.66
2014-09-30 $0.09B $0.01B 6.31
2014-06-30 $0.08B $0.01B 7.11
2014-03-31 $0.07B $0.01B 7.84
2013-12-31 $0.09B $0.01B 8.44
2013-09-30 $0.06B $0.01B 7.48
2013-06-30 $0.08B $0.01B 7.74
2013-03-31 $0.09B $0.01B 10.98
2012-12-31 $0.11B $0.01B 11.32
2012-09-30 $0.11B $0.01B 11.33
2012-06-30 $0.11B $0.02B 5.93
2012-03-31 $0.12B $0.02B 6.49
2011-12-31 $0.07B $0.02B 3.46
2011-09-30 $0.08B $0.02B 4.10
2011-06-30 $0.09B $0.02B 5.22
2011-03-31 $0.10B $0.02B 6.01
2010-12-31 $0.11B $0.02B 6.76
2010-09-30 $0.06B $0.01B 7.42
2010-06-30 $0.07B $0.01B 9.96
2010-03-31 $0.08B $0.01B 9.50
2009-12-31 $0.08B $0.01B 7.19
2009-09-30 $0.09B $0.02B 5.48
2009-06-30 $0.10B $0.02B 6.77
2009-03-31 $0.11B $0.01B 8.84
2008-12-31 $0.12B $0.01B 9.24
2008-09-30 $0.14B $0.02B 9.26
2008-06-30 $0.15B $0.02B 9.58
2008-03-31 $0.16B $0.02B 10.51
2007-12-31 $0.16B $0.02B 10.32
2007-09-30 $0.12B $0.01B 12.61
2007-06-30 $0.13B $0.01B 18.26
2007-03-31 $0.00B 0.00
2006-09-30 $0.00B 0.00
2006-06-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.799B $0.261B
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76